Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ASCO Seeking Immediate Oral Chemotherapy Coverage Under Medicare Part B

This article was originally published in The Pink Sheet Daily

Executive Summary

American Society of Clinical Oncology says Medicare Part B demonstration project covering oral chemotherapy is not enough. Group wants legislation to provide "transitional" coverage until full Medicare Rx benefit starts in 2006.

You may also be interested in...



Medicare Chemotherapy Bill Needed To Ensure Reimbursement Covers Cost, ASCO Says

American Society of Clinical Oncology interim measure would ensure oncologists’ Medicare Part B reimbursement for drugs cover acquisition costs. ASCO is collecting data to quantify losses to physicians due to payment changes made through Medicare Rx law.

GSK's Nucala Is Significantly Overpriced, ICER Draft Report Finds

New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS058612

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel